



Know Your NETs

Virtual Patient and Caregiver Conference

Saturday, July 18, 2026 | 11:00 a.m. – 4:00 p.m. ET

Presented by
Co-sponsors



Thank you to our additional sponsors

abbvie



CURIUM™
LIFE FORWARD

EXELIXIS®



TABLE OF CONTENTS

Scroll or click on the text or logos below to navigate to sections of the booklet. To return to the Table of Contents, click the round red TOC button at the end of each section. For optimal interactive performance, view this document in Read Mode.

	WELCOME.....	2
	AGENDA.....	3-4
	ASK QUESTIONS DURING THE CONFERENCE USING SLIDO.....	7
	FAST FACTS ABOUT NETS.....	8
	SPEAKER BIOGRAPHIES.....	11-14
	FROM OUR SPONSORS.....	16-28
	CLINICAL TRIALS.....	29
	SUPPORT NETRF.....	30-31
	A WORD OF THANKS.....	31

Note to Attendees

This patient and caregiver education conference is not intended as and shall not be relied upon as medical advice. The Neuroendocrine Tumor Research Foundation encourages all users to discuss any information provided with their oncologist, physician, and/or appropriate qualified health professional.

Attending this conference does not constitute a patient-physician relationship. The Neuroendocrine Tumor Research Foundation does not represent that any information provided here should supplant the reasoned, informed advice of a patient’s oncologist, physician, and/or appropriate qualified health professional.

WELCOME

We are honored to welcome you to our 7th annual Know Your NETs Virtual Conference, our premier patient and caregiver program. Whether you're newly diagnosed or years into your journey, this conference is designed to help you navigate life with neuroendocrine cancer and connect with a community who understands what you're facing. At NETRF, we're proud to be the largest global funder of neuroendocrine cancer research and a leading resource for trusted, patient-centered education.

Thanks to your input, the agenda is designed to align with your interests. We are fortunate to have a group of outstanding speakers—all experts in their fields—who have generously given their time to participate in this program.

You can submit your questions for our panel through SLIDO.com, using the event code NETRF. See the instructions for SLIDO in this booklet.

NETRF is grateful for all of our conference sponsors who have helped make this event possible. Please take a moment to review the educational content from our sponsors in this booklet. If you are looking for more information, check out NETRF's online [NET Knowledge Center](#).


Thank you for joining us today, supporting NETRF and, most importantly, being an active and engaged participant and community member. Your story matters and you are not alone. Together, we are committed to increasing understanding of neuroendocrine cancer for patients and their loved ones.



**Elyse
Gellerman, MHS**
Conference Co-Chair
CEO
*Neuroendocrine Tumor
Research Foundation*



**Xavier
Keutgen, MD**
Conference Co-Chair
*Associate Professor
of Surgery
UChicago Medicine*



**Andy
Liao, MD**
Conference Co-Chair
*Associate Professor
of Medicine
UChicago Medicine*



Neuroendocrine Cancer Patient & Caregiver Virtual Education Conference

Saturday, July 18, 2026
11:00 a.m. – 4:00 p.m. ET

AGENDA

This year's program builds on prior conferences with expanded foundational education, deeper insight into treatment decision-making, and a stronger focus on patient experience and long-term management.

Pre-Conference (On-Demand)

Neuroendocrine Cancer 101

A foundational session designed to help participants better understand their diagnosis and care.

Presenter: Chandrikha Chandrasekharan, MBBS; MD Anderson

Live Conference Agenda

I. Your NET Journey: From Diagnosis to Ongoing Care

Advancing knowledge through clinical insights and research updates

Recent Advances in the Clinic: What's New in Neuroendocrine Cancer Treatment and Clinical Trials

Presenter: Andy Liao, MD; UChicago Medicine

Advances in Research: The Future of Neuroendocrine Cancer Care

Presenter: Anna Greene, PhD, Chief Scientific Officer, NETRF

What Happens After Your Diagnosis: Monitoring, Surveillance and Ongoing Care

Presenter: Udhayvir Grewal, MBBS; Emory University

Understanding the Long-term Impact of Treatment

Presenter: Thor Halfdanarson, MD; Mayo Clinic

Thrivership I: Knowledge Is Power Followed by a Short Break

II. How Treatment Decisions Are Made: Inside the Care Team

Exploring how care teams collaborate and how treatment decisions are made

Inside a Tumor Board: How Doctors Make Treatment Decisions

Moderator: Xavier Keutgen, MD; UChicago Medicine

Panelists: Andy Liao, MD; UChicago Medicine, Udhayvir Singh Grewal, MBBS; Emory University, Thor Halfdanarson, MD; Mayo Clinic, Aman Chauhan, MD; University of California, San Francisco, Kimberly Perez, MD; Dana-Farber Cancer Institute

Treatments for Faster-Growing Neuroendocrine Cancers (NECs & Grade 3 Cancers)

Presenter: Aman Chauhan, MD; University of California, San Francisco

Physicians and Patients: Real Conversations About Treatment Choices – When is Surgery an Option?

Presenter: Xavier Keutgen, MD; UChicago Medicine

Physicians and Patients: Real Conversations About PRRT and Targeted Therapy Options

Presenter: Andy Liao, MD; UChicago Medicine

Thrivership II: Resilience and Uncertainty Followed by a Short Break



Agenda, cont.

III. Living Well with NETs: Managing Symptoms and Moving Forward

Supporting quality of life through symptom management and shared experience

Common Symptoms of Neuroendocrine Cancer: What to Expect and When to Speak Up

Presenter: Kimberly Perez, MD; Dana-Farber Cancer Institute

Heart Health and Neuroendocrine Cancer: What to Watch For

Presenter: Tamar Polonsky, MD; UChicago Medicine

Bone Health and Neuroendocrine Cancer: Managing Pain and Treatment

Presenter: Vasyl Hereha, MD; UChicago Medicine

Thrivership: Emotional Wellness in the Face of Uncertainty

Presenter: Jessica Thomas, Director of Patient Education, NETRF

Thrivership III: What Matters Most Followed by a Short Break

IV. Ask the Experts: Live Q&A

An interactive session with conference speakers to address audience questions.

Program subject to change.

Co-sponsored by



Thank you to our additional sponsors





BECOME INFORMED, ENGAGED AND CONNECTED IN YOUR NET JOURNEY

Current and accurate patient education and information is vital to helping you live well with neuroendocrine cancer. We know that finding credible information and education can be challenging and difficult to navigate.

NETRF's NET Knowledge Center is a comprehensive resource organized to direct you to the information you need to be engaged in your neuroendocrine cancer journey while connecting you to a community of resources.

INFORMATION

Learn more about neuroendocrine cancers

A diagnosis of neuroendocrine cancer often comes with many questions and concerns. These resources explain the various types of neuroendocrine cancers, diagnostic tests, and risks so you and your family can better understand your condition.

ENGAGEMENT

Take the next step regarding your diagnosis

With many different kinds of neuroendocrine cancers, it's important to find the best possible care and treatment. These resources explore finding specialists, treatments, and how best to care for yourself.

COMMUNITY

Connect with more people and resources about neuroendocrine cancer


When it comes to neuroendocrine cancer, it takes a community. Explore the many ways you can access the latest information on treatments and research progress, and what's happening in the neuroendocrine cancer community.



Visit the NET Knowledge Center at
netrf.org/for-patients/ or scan this QR code.

Updated guide
coming soon!

Neuroendocrine Cancer: A Guide for Patients and Families



NETRF's 100-page guide to neuroendocrine cancer is a hands-on reference for the tests, treatments, and management of gastrointestinal, pancreatic, lung, and adrenal neuroendocrine tumors. It offers a solid overview of neuroendocrine cancer for the recently diagnosed patient, serves as a helpful reference for longer-term survivors, and gives practical tips on managing symptoms, and patient/provider communication for those at any stage of the disease.

To order your copy visit,
netrf.org/for-patients/
or scan the QR code here:



ASK QUESTIONS ONLINE THROUGH SLIDO!



OPTION 1

- On your phone, tablet, or computer, open your web browser and go to www.slido.com, then select our event code: **NETRF** (screen 1)
- Click on **Live Interaction** (screen 2). That's it! You are ready to ask a question or vote a question up (screen 3). There's no need to duplicate a question.


OPTION 2

- Click [this link](#) to automatically go to the Questions page.


Do NOT use your name. Please ask your question anonymously or use your initials.

While we cannot guarantee your question will be addressed, questions with the highest number of votes stand a better chance of getting answered by a speaker.


Screen 1



Screen 2



Screen 3



Fast Facts About NETs

- Neuroendocrine cancer is an uncommon cancer and the incidence has been increasing in recent decades. This is attributed in part to improvements in diagnostic techniques and greater awareness.
- Approximately **28,000** people in the United States are diagnosed with a neuroendocrine cancer each year, and nearly **250,000** are living with one today.
- The average length of time from first symptoms to diagnosis is **4.3 years**.¹
- The average number of health care visits made before a neuroendocrine cancer diagnosis is **11.8 visits**.¹
- Up to **58% of patients** had metastases at diagnosis.

¹ Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;3(1):43-53.

ABOUT THE NEUROENDOCRINE TUMOR RESEARCH FOUNDATION (NETRF)

The Neuroendocrine Tumor Research Foundation is the largest global funder of neuroendocrine cancer research, investing \$43 million in landmark research since 2005. NETRF's mission is to drive transformational discoveries in the study of neuroendocrine cancers. We are leading the fight to bring life-changing treatments to families and to find a cure.



NETRF:

- Invests boldly in the most promising scientific projects worldwide
- Funds and nurtures the most brilliant neuroendocrine cancer scientists who bring their original thinking and determined spirit to their work
- Offers hope to patients and families
- Shapes the future of neuroendocrine cancer care to save lives

NETRF's impact on the field of neuroendocrine cancer research has been profound. Thanks to NETRF-funded discoveries and the efforts of the neuroendocrine cancer medical community, the therapeutic landscape of neuroendocrine cancer management looks entirely different now than it did in 2005, when NETRF began. Such advances are not random. They are the direct result of many years of NETRF-funded research.

\$43M in NETRF funded breakthrough science

22 clinical trials fueled by NETRF-supported research



171

research projects funded



81

institutions in 17 countries



8

new therapies since NETRF began



View our 2025 Annual Report to explore the major milestones we reached over the past year.

EDUCATING AND EMPOWERING PATIENTS


NETRF is dedicated to the thousands of patients, families, and caregivers affected by neuroendocrine cancer. We provide expert educational resources to help you understand your diagnosis, make informed health care decisions, and thrive.

Our resources include:



NET Knowledge Center

A comprehensive online resource for information, engagement, and community building



Neuroendocrine Cancer Guide

A hands-on reference for the tests, treatments, and management of neuroendocrine cancer



NETWise Podcast series

Insights and perspectives on living with neuroendocrine cancer



NETRF YouTube library

Videos about diagnosis, treatment, research, and living with neuroendocrine cancer



Patient and caregiver education conferences

In-person and virtual events for knowledge- and community-building



Searchable databases

Includes neuroendocrine cancer doctors and multidisciplinary treatment programs



Visit netrf.org/for-patients/ or scan the QR code.

SPEAKER BIOGRAPHIES



Elyse Gellerman, MHS

Chief Executive Officer, NETRF

Elyse has been Chief Executive Officer of the Neuroendocrine Tumor Research Foundation since November 2017. As CEO, she has built a team that has vastly expanded NETRF's global reach in research funding and patient education. Prior to NETRF, Elyse was a Regional Vice President for Sarah Cannon, the oncology service line for Hospital Corporation of America (HCA). Elyse spent more than 20 years in hospital service line development, operations consulting, and marketing. She has served on the national board at Susan B. Komen, and been a member of other health-related nonprofit boards. In 2011, Elyse was recognized by the Obama Administration as a Champion for Change in the fight against breast cancer. Elyse graduated from Cornell University and has a master's degree in healthcare systems from the University of Denver.



Xavier Keutgen, MD

UChicago Medicine

Dr. Keutgen is a surgical oncologist with particular expertise in treating neuroendocrine, thyroid, parathyroid and adrenal tumors. He is the Co-Director of the University of Chicago Neuroendocrine Tumor Center and works closely with a multidisciplinary team that specializes in NETs. Dr. Keutgen, a Belgian native, received his medical degree from the University of Heidelberg (Germany) and completed his residency at New York Presbyterian Hospital-Weill Cornell Medical Center and fellowships at the University of Zurich (Switzerland) and the National Cancer Institute (NIH).



Chandrikha Chandrasekharan, MBBS

MD Anderson Cancer Center

Dr. Chandrasekharan is a Clinical Associate Professor at MD Anderson Cancer Center, where she has focused on neuroendocrine tumors and pancreatic cancer since January 2025. She is a dual board-certified physician in Medical Oncology and Palliative Medicine. Prior to joining MD Anderson, Dr. Chandrasekharan served for eight years as a Clinical Associate Professor at the University of Iowa. There, she co-led the gastrointestinal oncology program and treated a broad range of GI malignancies. From 2021 to 2022, she was Co-Director of the Clinical Core for the Neuroendocrine Tumor SPORE. She is an active member of the North American Neuroendocrine Tumor Society (NANETS), currently serving as Co-Chair of the NANETS Annual Symposium Planning Committee, and previously chaired the Regional Medical Education Committee. In addition to her clinical and academic work, Dr. Chandrasekharan is engaged in clinical trials and research focused on healthcare outcomes, health equity, and global oncology care.

SPEAKER BIOGRAPHIES, cont.



Aman Chauhan, MD

University of California, San Francisco

Aman Chauhan, MD, is an Associate Professor of Medicine at UCSF. He earned his medical degree from Kasturba Medical College in Manipal, India, completed a dual residency in internal medicine and pediatrics at Louisiana State University, and a hematology-oncology fellowship at the University of Kentucky, where he developed expertise in neuroendocrine tumors. He also completed a physician externship through the National Cancer Institute's Cancer Therapy Evaluation Program, focusing on clinical trial design and research. Dr. Chauhan's clinical and research interests center on neuroendocrine neoplasms, including both well-differentiated and poorly differentiated disease. He serves as national principal investigator for several investigator-initiated neuroendocrine cancer clinical trials and holds leadership roles with the AJCC, ASCO, SWOG Neuroendocrine Tumor Subcommittee, and the North American Neuroendocrine Tumor Society.



Anna Greene, PhD

Chief Scientific Officer, NETRF

As NETRF's Chief Scientific Officer, Dr. Greene leads the foundation's research programs, oversees the annual grant cycle, supervises post-award processes, organizes the annual research symposium, and reports research impact and outcomes to the community. She is motivated to help advance neuroendocrine cancer research to understand the disease better and ultimately identify better treatments and cures. She earned a BS in chemistry from Berry College and a PhD in chemistry from Dartmouth College.



Udhayvir S. Grewal, MBBS

Emory University

Dr. Grewal is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves as co-chair of the North American Neuroendocrine Tumor Society (NANETS) NETPact Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. He completed his internal medicine residency at LSU Health Sciences Center-Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he remains an active collaborator with the University of Iowa NET SPORE team.

SPEAKER BIOGRAPHIES, cont.



Thor Halfdanarson, MD

Mayo Clinic

Dr. Halfdanarson is a professor of Oncology at the Mayo Clinic College of Medicine and Science and a consultant in Medical Oncology at the Mayo Clinic. He specializes in GI oncology with a focus on NETs and cancers of unknown primary, serves as the Chair of the Hepato-Pancreato-Biliary (HPB) Disease Group for the Mayo Clinic Comprehensive Cancer Center, the Chair of Education for the Department of Oncology at Mayo Clinic, Rochester, and is the co-chair of the Pancreatic/ Neuroendocrine Tumor Board. Dr. Halfdanarson is a member of the NCCN guidelines panel for NETs, the Co-Chair of the NET Group at Alliance for Clinical Trials in Oncology and a President Emeritus of NANETS.



Vasyl Hereha, MD

UChicago Medicine

Dr. Hereha is an Assistant Professor of Medicine at the University of Chicago. He completed a Family Medicine residency, before completing a fellowship in Hospice and Palliative Medicine at the University of Chicago. He is now a palliative medicine clinician who works inpatient and has an outpatient palliative medicine clinic embedded within the University of Chicago Comprehensive Cancer Center. His scholarly interests include medical education and clinician wellness. He serves as the Program Director for the University of Chicago Hospice and Palliative Medicine Fellowship and the Medical Director of UCM Hospice.



Chih-Yi (Andy) Liao, MD

UChicago Medicine

Dr. Liao is an Associate Professor of Medicine at the University of Chicago. He is a medical oncologist and clinical investigator who specializes in treating gastrointestinal neuroendocrine tumors and hepatobiliary cancers. He leads and conducts many clinical trials for these cancers. He serves as the Medical Director of the University of Chicago's Hematology/Oncology Clinic, the Interim Director of the Gastrointestinal Oncology Program and the Co-Director of the Neuroendocrine Tumor Program.



Kimberly Perez, MD

Dana-Farber Cancer Institute

Dr. Perez is an Assistant Professor of Medicine at Harvard Medical School, Senior Physician and Co-Director of Gastrointestinal Oncology Clinical Trials Program at Dana-Farber Cancer Institute in Boston. She is a medical oncologist and clinical investigator who specializes in inherited cancer syndromes and treatment of neuroendocrine and pancreaticobiliary cancers. She serves as the principal investigator of many clinical trials for these cancers.

SPEAKER BIOGRAPHIES, cont.



Tamar Polonsky, MD, MSCI

UChicago Medicine


Tamar Polonsky, MD, MSCI, is a general cardiologist who treats a wide range of cardiac conditions, including coronary artery disease, hypertension, hyperlipidemia (high cholesterol) and valve disease. She also specializes in the management of heart disease in cancer patients (cardio-oncology). She works closely with oncologists and surgeons to take care of patients with preexisting heart disease and to help monitor for potential cardiac complications from chemotherapy and radiation. Dr. Polonsky has research expertise in cardiovascular epidemiology and prevention. She has experience analyzing data from large cohort studies, with the aim of finding novel ways to predict a person's risk of developing heart disease.



Jessica Thomas, LCSW

Director of Patient Education, NETRF

Jessica Thomas, LCSW, is a clinical social worker with nearly 20 years of experience supporting patients and caregivers navigating neurology, oncology, and chronic illness. With a career rooted in mental health care for those facing complex medical conditions, Jessica is deeply committed to helping individuals and families identify and embrace what matters most to them while living with chronic, progressive, or terminal illness. She is passionate about fostering community, advancing patient-centered care, supporting research, and improving the overall patient experience and outcomes.



NETwise

A Podcast About Neuroendocrine Cancer

Being diagnosed with neuroendocrine cancer, an uncommon disease, can feel isolating and overwhelming. The NETWise podcast is here to help patients and caregivers navigate the world of neuroendocrine tumors and carcinomas.

Listen as the NET Research Foundation (NETRF) speaks with experts and patients who will help you to understand diagnosis, treatment, thrivership and everything in between. NETWise is for everyone, from newly diagnosed patients to longtime survivors, as well as caregivers and family members.

This is your guide to learning, listening, knowing, and being NETWise.

Check out these episodes for more on what you have heard during KNOW YOUR NETs:

- [Care for the Neuroendocrine Carcinoma Caregiver](#)
- [Understanding Neuroendocrine Carcinoma](#)
- [Managing the Financial Burden of Neuroendocrine Cancer](#)
- [Radiopharmaceutical Treatment: FAQs and Insights](#)
- [How Could AI Change Neuroendocrine Cancer](#)
- [Finding Happiness While Living With Neuroendocrine Cancer](#)
- [Managing Symptoms of NENs](#)

Subscribe [here](#) and find our entire NETWise library. Listen to NETWise wherever you get your podcasts.



Neuroendocrine Tumor
Research Foundation
100 Hancock Street, Third Floor
Quincy, MA 02171
(617) 946-1780 | netrf.org



**THANK YOU TO OUR
PROGRAM SPONSORS**

Neuroendocrine Tumor Program



UChicago Medicine

Comprehensive Cancer Center

One of the highest volume centers in the country, the **University of Chicago Medicine Neuroendocrine Tumor (NET) Program** offers unique therapy options for even the most advanced cancers. We offer:

- A multidisciplinary program consisting of nationally recognized experts who specialize in diagnosing and treating all forms of NETs.
- A multidisciplinary in-person and virtual clinic that allows you to be seen by our oncologists and surgeons at the same time.
- A dedicated NET nurse navigator to guide you through the program and facilitate your treatment plan in collaboration between specialists.
- The most advanced surgical techniques, including minimally invasive/robotic procedures and complex approaches to remove and destroy NETs that have spread to the liver.
- Leading-edge technologies like precision-enhancing navigation-controlled ablation of liver tumors and liver tumor histotripsy.
- The only medical cyclotron in the region for creating novel radiotracers for NETs, which helps create next-generation PRRT treatments in-house.
- Molecular profiling of NETs allowing for a personalized approach using therapies that work best on your tumor.
- One of the most experienced genetic counseling programs in the country to treat patients with NETs linked to hereditary conditions.
- Researchers conducting the latest studies on NETs, both in the laboratory and the clinic.



Research areas of focus and impact



Population research



Translational research



Cancer genetics and immunotherapy



New treatments, early phase clinical trials

Recognized as an NCI Designated Comprehensive Cancer Center

UChicago Medicine is also recognized for the comprehensive nature of our research, care, education and community outreach programs. We are one of only two institutions in the state of Illinois — and 51 in the United States — to be recognized as a comprehensive cancer center. In addition, we have been named as a member institution of the National Comprehensive Cancer Network (NCCN), an alliance of 33 leading cancer centers in the United States.



Meet the Neuroendocrine Tumor Team



Xavier Keutgen, MD
Endocrine Surgery



Chih-Yi Liao, MD
*Hematology and
Oncology (Cancer)*



Abdul Khan, MD
Radiology



Daniel Appelbaum, MD
Nuclear Medicine



Uzma D. Siddiqui, MD
*Interventional
Endoscopy and
Gastroenterology*



Namrata Setia, MD
Pathology

Get a Second Opinion

Seeking the opinion of an expert can ease your mind and help you feel more secure in the decisions you are making. At UChicago Medicine, we offer both on-site and remote second opinions. In addition to recommending standard therapies, our physicians may also offer innovative treatment options not widely available at most hospitals, including clinical trials that may be right for you.

**To learn more, call
1-855-702-8222
or visit
UChicagoMedicine.org/cancer-appointment.**



Our dedicated nurse navigator will guide you through the program and facilitate your treatment plan in collaboration with our multidisciplinary team.

**To make an appointment, call 800-824-0200
or email NETS@uchospitals.edu**

abbvie




Boehringer
Ingelheim



The CAREFNDR study is a phase 3 clinical study for adults living with **carcinoid syndrome** associated with NETs.




Scan the QR Code for more information about the CAREFNDR study or visit **CAREFNDR.com**



BRAVESST-2 study is a first-in-human Phase 1/2 clinical study for adults living with a neuroendocrine tumor, neuroendocrine carcinoma, or other solid tumor that expresses somatostatin receptor type-2 (SST2).





A world leader in nuclear medicine, Curium is driven to advance patient care

100% Focus

on radiopharmaceuticals

100% Committed

to partnering with hospitals, providers, advocacy groups, and patients to improve the cancer care experience



RAYTHERITY[®]
(lutetium Lu 177 edotreotide)
injection for intravenous use



COMING SOON

Scan the QR code to learn more



© 2026 ITM USA, Inc. All rights reserved. ITM[®] and RAYTHERITY[®]
are registered trademarks of ITM Isotope Technologies Munich SE.
M-US-RAY-0009 | April 2026

EXELIXIS®



RayzeBio



Innovation that makes an impact

Learn more about our
passion to **Find, Fight
and Follow[®]** disease
to deliver better patient
outcomes.



Visit us:
Lantheus.com



LANTHEUS[®]

 [@Lantheus](https://www.linkedin.com/company/Lantheus)

End-to-end solutions to help accelerate patient access

For treatment centers and referring providers



Insurance Support

- Benefits investigation
- Prior authorization requirements
- Appeals support
- Billing, coding, and reimbursement education (for treatment centers only)



Financial Support

- Eligible patients may pay as little as \$0 per dose. Subject to terms and conditions. Limitations apply*
- Enrollment is required to determine eligibility and participation



Accessing Treatment

- Access to ROME ordering platform
- Help with product ordering
- Real-time delivery tracking
- Treatment center locator
- Additional offerings available for referring sites



Patient Education

Live 1-on-1 support is available for patients starting treatment. Our Patient Navigators can help answer the most common treatment questions.

Our team is available to assist you every step of the way

Patient Navigators assist treatment centers and referring offices with access, reimbursement, and affordability services. They can also provide 1-on-1 patient education.

Phone: 1-844-638-7222

Customer Support Associates assist treatment centers with product ordering and delivery.

Phone: 1-844-367-3222


Your local Access and Reimbursement Field Representative is available to assist you with all our support services.

ROME, radiopharmaceutical order management environment.

CLINICAL TRIALS

Clinical trials can provide patients with innovative treatments and are the final step in a long process that begins with research in a lab. Before any new treatment is used in people in clinical trials, researchers work for many years in the lab to understand its effects by testing it first on cells or in animals. They then work to determine the best dose for treatment, the side effects the drug may cause, and how the effectiveness of the drug compares to current treatments. It can take 10–15 years to develop a new drug to the point of a first clinical trial. Our online NET Trial Finder can connect you to clinical trials in your area.

NET Trial Finder



The screenshot shows the NET Trial Finder website. At the top, there is a navigation bar with the NET logo, the text "NEUROENDOCRINE TUMOR RESEARCH FOUNDATION", a small "powered by" logo for "ancora.ai", and links for "LEARN", "LOGIN", and "SIGN UP". Below the navigation bar, the main heading is "MATCH & CONNECT" followed by "Finding clinical trials made simple". A subtext states: "Clinical trials can provide patients with innovative treatments. Ancora.ai helps find your personalized trial options. It's easy, fast, and free." To the right of the text is an illustration of a stethoscope, a computer monitor displaying a checklist, and a pill bottle. Below this is a search bar with a dropdown menu set to "Neuroendocrine tumors/cancer", a text input field for "Enter city and country", and a "Find Trials" button. At the bottom, there is a section titled "Explore trials by category" with a button for "Radiopharmaceuticals" and a right arrow.



FIND A CLINICAL TRIAL

There are many clinical trials for neuroendocrine cancer. Scan this QR code to access the NET Trial Finder, or visit netrf.org/for-patients/trial-finder/

Find it early. Treat it better. Cure it faster.



“I truly believe in the mission and the great work that NETRF is doing year in and year out. I want to be part of the solution — and I want to see a future where we find a cure.”

— Steve Kaufer,
NETRF Board Member,
Co-Founder, TripAdvisor,
Co-Founder, Give Freely

For over 20 years, NETRF has led the global charge to transform neuroendocrine cancer treatment.

Now, we’ve launching our most ambitious campaign yet — a **\$25 million** effort to accelerate the bold science that will deliver new therapies and, ultimately, cures.

With your support, NETRF is advancing progress in three urgent and high-impact areas:

- **Early Detection** — So patients are diagnosed sooner, when treatment is more effective
- **New Therapeutic Development** — To expand treatment options and improve survival
- **Personalized Treatments** — To ensure every patient receives the right care at the right time

Researchers are ready. Bold ideas are waiting. They just need our support.

Your Impact So Far:



171

research projects
funded



81

institutions in
17 countries



70%

increase in research
proposals since 2023

\$43 million

invested in breakthrough science

22

clinical trials fueled by
NETRF-supported research



Early Detection



CURES



This Is the Moment to Create Tomorrow's Cures

The discoveries happening today — in labs, clinics, and collaborative research teams — are transforming what's possible for patients and families facing neuroendocrine cancer.

But breakthroughs need you.

Your gift drives progress by:


- Funding life-changing research led by the world's leading scientists
- Powering innovations like CAR T-cell therapy from lab to lives
- Equipping patients and caregivers with trusted education and resources

Research is accelerating and momentum is building. Now's the time to double down on our mission.

Make your gift today! Visit netrf.org/breakthroughs or scan the QR code to learn more.



**Breakthroughs Today, Cures Tomorrow.
Our future starts now.**



«
TOC

A WORD OF THANKS

Thank you for taking part in NETRF's 2026 KNOW YOUR NETs Virtual Patient and Caregiver Education Conference. We hope you found the sessions informative and valuable.

If you have any questions about NETRF, our research and resources, and how we can best support you on your journey with neuroendocrine cancer, please contact us at info@netrf.org.

We are grateful to our generous partners and friends like you. Thanks to your support, NETRF can host educational conferences and advance research, opening new doors to neuroendocrine cancer discoveries.

NETRF greatly appreciates the generosity of the following sponsors who made this educational program possible. Thank you!

Presented by Co-sponsors



Additional support provided by



Visit our YOUTUBE channel for patient education videos.



Connect with us and other patients, caregivers, and family members online:

